# Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden

> **NCT06769256** · PHASE4 · RECRUITING · sponsor: **Henan Institute of Cardiovascular Epidemiology** · enrollment: 300 (estimated)

## Conditions studied

- ST-segment Elevation Myocardial Infarction (STEMI)

## Interventions

- **DRUG:** rhTNK-tPA, 4-8 mg
- **DRUG:** Tirofiban

## Key facts

- **NCT ID:** NCT06769256
- **Lead sponsor:** Henan Institute of Cardiovascular Epidemiology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06769256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06769256, "Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06769256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*